Cargando…
Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272631/ https://www.ncbi.nlm.nih.gov/pubmed/37333047 http://dx.doi.org/10.1177/20363613231183785 |
| _version_ | 1785059540894482432 |
|---|---|
| author | Fareed, Areeba Inam, Nimrah Faraz, Fatima |
| author_facet | Fareed, Areeba Inam, Nimrah Faraz, Fatima |
| author_sort | Fareed, Areeba |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10272631 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102726312023-06-17 Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar Fareed, Areeba Inam, Nimrah Faraz, Fatima Rare Tumors Letter to the Editor SAGE Publications 2023-06-10 /pmc/articles/PMC10272631/ /pubmed/37333047 http://dx.doi.org/10.1177/20363613231183785 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Fareed, Areeba Inam, Nimrah Faraz, Fatima Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar |
| title | Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar |
| title_full | Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar |
| title_fullStr | Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar |
| title_full_unstemmed | Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar |
| title_short | Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar |
| title_sort | breakthrough treatment choice for acute myeloid leukemia in pediatric and adult patients: revumenib, an oral selective inhibitor of kmta2ar |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272631/ https://www.ncbi.nlm.nih.gov/pubmed/37333047 http://dx.doi.org/10.1177/20363613231183785 |
| work_keys_str_mv | AT fareedareeba breakthroughtreatmentchoiceforacutemyeloidleukemiainpediatricandadultpatientsrevumenibanoralselectiveinhibitorofkmta2ar AT inamnimrah breakthroughtreatmentchoiceforacutemyeloidleukemiainpediatricandadultpatientsrevumenibanoralselectiveinhibitorofkmta2ar AT farazfatima breakthroughtreatmentchoiceforacutemyeloidleukemiainpediatricandadultpatientsrevumenibanoralselectiveinhibitorofkmta2ar |